Medtronic plc. · NYSE:MDT

Medtronic — Technical Presentation (August 2018)

20 slides from Medtronic's technical presentation, August 2018

  1. Slide 1: 2018 ESC Syncope Guidelines Summary

    2018 ESC SYNCOPE GUIDELINES SUMMARY

  2. Slide 2: Overview of Updated Recommendations Since 2009

    GUIDELINES OVERVIEW OF UPDATED RECOMMENDATIONS SINCE 2009

  3. Slide 3: Goals of 2018 Task Force

    2018 EUROPEAN SOCIETY OF CARDIOLOGY SYNCOPE GUIDELINES Goals of 2018 Task Force1 Reducing Cost & Providing Practical Driving Multidisciplinary Admissions: Guidance: Approach: Focus of recommendations is Guidelines include clinical Most multidisciplinary syncope on the need to reduce hospital recomme

  4. Slide 4: New Concepts in 2018 Guidelines

    2018 EUROPEAN SOCIETY OF CARDIOLOGY SYNCOPE GUIDELINES New Concepts in 2018 Guidelines1 Extensive changes based on new evidence: § Increased role of prolonged ECG monitoring with ILR § Revised recommendation from Class I to Class II for Holter monitors and tilt tests § Increased importance of risk s

  5. Slide 5: Guidelines Recommendation Classifications

    GUIDELINES RECOMMENDATION CLASSIFICATIONS1 Class I, Level of evidence “A” is HIGHEST recommendation 1 Brignole M, et al. Eur Heart J. 2018;39:1883-1948. Table 1 and Table 2 in Guidelines Introduction. 2018 ESC Guidelines for Diagnosis and Management of Syncope | August 2018

  6. Slide 6: Comparison of Changes in ILR Recommendations

    COMPARISON OF CHANGES IN ILR RECOMMENDATIONS 2009 Guidelines1 2018 Guidelines2 Class I Level B Class I Level A § Indicated in early phase evaluation in patients with § Indicated in early phase evaluation in patients with recurrent syncope of uncertain origin, absence of recurrent syncope of uncertai

  7. Slide 7: T-LOC Monitoring Recommendations

    T-LOC MONITORING RECOMMENDATIONS T-LOC suspected syncope Certain diagnosis/mechanism Uncertain Diagnosis Treat appropriately Syncope T-LOC Non-syncopal High risk* Low risk* Low risk* Low risk* Unconfirmed epilepsy arrhythmia arrhythmia likely and reflex likely and need and rare episodes or likely re

  8. Slide 8: Evidence Support: Recommendations for Diagnosing Unexplained Syncope

    EVIDENCE SUPPORT RECOMMENDATIONS FOR DIAGNOSING UNEXPLAINED SYNCOPE

  9. Slide 9: Evidence Support in Guidelines: ILR Diagnostic Yield 3.6X

    EVIDENCE SUPPORT IN GUIDELINES 2009 2018 ILR is indicated in an early phase of evaluation in patients with recurrent syncope of Class I Class I uncertain origin, absence of high-risk criteria, and a high likelihood of recurrence within the battery life of the device. LOE: B LOE: A § NEW — Meta-analy

  10. Slide 10: Evidence Support in Guidelines: High-Risk Patients

    EVIDENCE SUPPORT IN GUIDELINES 2009 2018 ILR is indicated in patients with high-risk criteria in whom a comprehensive evaluation Class I Class I did not demonstrate a cause of syncope or lead to a specific treatment, and who do not have conventional indications for primary prevention ICD or pacemake

  11. Slide 11: Evidence Support in Guidelines: Reflex Syncope

    EVIDENCE SUPPORT IN GUIDELINES 2009 2018 ILRs should be considered in patients with suspected or certain reflex syncope Class Ila Class Ila presenting with frequent or severe syncopal episodes. LOE: B LOE: B ILR monitoring in reflex syncope patients to identify those that benefit from cardiac pacing

  12. Slide 12: Evidence Support in Guidelines: Cost-Effectiveness

    EVIDENCE SUPPORT IN GUIDELINES 2009 2018 ILR is indicated in an early phase of evaluation in patients with recurrent syncope of Class I Class I uncertain origin, absence of high-risk criteria, and a high likelihood of recurrence… LOE: B LOE: A Holter monitoring should be considered in patients who h

  13. Slide 13: Evidence Support: Expanded Recommendations for Diagnosing T-LOC

    EVIDENCE SUPPORT EXPANDED RECOMMENDATIONS FOR DIAGNOSING T-LOC

  14. Slide 14: Evidence Support in Guidelines: Unexplained Falls

    EVIDENCE SUPPORT IN GUIDELINES NEW 2018 Class IIb ILR may be considered in patients with unexplained falls. LOE: B § “Despite the lack of controlled trials and an overall modest quality of studies, there is strong consensus that the management of unexplained falls should be the same as that for unex

  15. Slide 15: Evidence Support in Guidelines: Unconfirmed Epilepsy

    EVIDENCE SUPPORT IN GUIDELINES NEW 2018 ILR may be considered in patients in whom epilepsy was suspected but the treatment Class IIb has proven ineffective. LOE: B § “Syncope and Epilepsy have similar clinical features, including abrupt T-LOC without warning, abnormal limb movements such as myocloni

  16. Slide 16: Evidence Support in Guidelines: ILR Instead of ICD

    EVIDENCE SUPPORT IN GUIDELINES NEW 2018 Instead of an ICD, an ILR may be considered in patients with recurrent episodes of unexplained syncope Class IIb who are at low risk for SCD and without current indication for ICD. LOE: C § Unexplained syncope in this population is defined as “suspected arrhyt

  17. Slide 17: 2018 ESC Syncope Guidelines: Conclusions

    2018 ESC SYNCOPE GUIDELINES: CONCLUSIONS § The increasing need to reduce inappropriate admissions & tests and new 1 evidence led to creation of the 2018 ESC Syncope Guidelines § ILR recommendation upgraded from a Class I/Level B to a Class I/Level A for unexplained syncope as meta-analysis shows 3.6

  18. Slide 18: Risk Assessment Recommendations

    *RISK ASSESSMENT RECOMMENDATIONS1 Assessment of Syncopal Event Low risk High risk (red flag) 1. Associated with prodrome typical of reflex syncope (e.g., Major light-headedness, feeling of warmth, sweating, nausea, 1. New onset of chest discomfort, breathlessness, abdominal vomiting) pain, or headac

  19. Slide 19: Risk Assessment Recommendations: Physical Examination and ECG

    *RISK ASSESSMENT RECOMMENDATIONS1 Physical Examination Low risk High risk (red flag) 1. Normal examination Major 1. Unexplained systolic BP in the ED < 90 mmHg 2. Suggestion of gastrointestinal bleed on rectal examination 3. Persistent bradycardia (< 40 bpm) in awake state and in absence of physical

  20. Slide 20: Brief Statement

    Brief Statement See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan ™ device, see the MRI SureScan technical manual before performing an

Medtronic — Technical Presentation (August 2018) on 6ix